Pfizer Inc. (PFE)

41.67
NYSE : Health Technology
Prev Close 41.59
Day Low/High 41.48 / 41.81
52 Wk Low/High 35.32 / 46.47
Avg Volume 23.36M
Exchange NYSE
Shares Outstanding 5.55B
Market Cap 230.23B
EPS 1.90
P/E Ratio 21.89
Div & Yield 1.44 (3.33%)

Latest News

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), In Patients Aged 12 And Older With Moderate To Severe Atopic Dermatitis

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), In Patients Aged 12 And Older With Moderate To Severe Atopic Dermatitis

Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and...

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Attorneys general from 44 states allege the nation's largest generic drugmakers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs.

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

U.S. stock futures fall sharply after China vows to stand its ground in the escalating trade war with the United States; oil prices surge after Saudi Arabia alleges two of its tankers were victims of a 'sabotage attack,' Teva and other drugmakers are alleged to have conspired to artificially inflate and manipulate prices for generic drugs.

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales

Shares of Puma Biotechnology plunge after the company reveals that more patients than expected have discontinued treatment with its breast cancer drug, Nerlynx, prompting several analyst downgrades.

Sweet Taste of Fear

Sentiment's shifting, we're getting oversold and it looks like fear and panic are creeping in -- that's the way it should be.

Pfizer Acquires Clinical-Stage Biotech Therachon

Pfizer Acquires Clinical-Stage Biotech Therachon

Pfizer (NYSE: PFE) today announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the...

European Commission Approves LORVIQUA® (lorlatinib) For Certain Adult Patients With Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

European Commission Approves LORVIQUA® (lorlatinib) For Certain Adult Patients With Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) granted conditional marketing authorization for LORVIQUA ® (lorlatinib, available in the U.

Pfizer Gets FDA Approval for $225,000 Heart Disease Drug

Pfizer Gets FDA Approval for $225,000 Heart Disease Drug

The FDA approves Pfizer's treatment for a rare form of heart disease.

S&P Closes at Record High as Alphabet Weighs Down Nasdaq

S&P Closes at Record High as Alphabet Weighs Down Nasdaq

Stocks ended mixed as the S&P 500 set a record close and the Nasdaq slumped on a revenue miss from Alphabet.

Pfizer Lifts 2019 Earnings Forecast as Biopharma Sales Drive Q1 Profit Beat

Pfizer Lifts 2019 Earnings Forecast as Biopharma Sales Drive Q1 Profit Beat

Pfizer posted stronger-than-expected first quarter earnings Tuesday, and boosted the mid-point of its full-year profit forecast thanks to anticipated gains in consumer healthcare.

Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon

Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon

We also dissect the S&P 500's record run, check out China's latest economic data and take a skeptical glance at an idea floated by a couple Fed officials.

Stocks Drift As Google Sales Miss, China Factory Slip, Clips Record S&P 500 High

Stocks Drift As Google Sales Miss, China Factory Slip, Clips Record S&P 500 High

Global stocks slipped lower for a second consecutive session Tuesday, pulling U.S. equity futures into the red, as investors reacted to renewed weakness in China's manufacturing sector and braced for the impact of softer-than-expected revenue gains from online ad giant Alphabet Inc.

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS

Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2019 and raised the midpoint of its 2019 financial guidance for adjusted diluted EPS (2).

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

U.S. stock futures are mixed after Alphabet posts its weakest revenue gains since 2016; Apple, Advanced Micro Devices, General Electric and General Motors report earnings; BP's first-quarter profit tops forecasts.

Dow Futures Gain as Solid Growth, Tame Inflation, Surprising Profits Drive Bulls

Dow Futures Gain as Solid Growth, Tame Inflation, Surprising Profits Drive Bulls

Global stocks were mixed Monday as investors extended bets that surging economic growth, stronger-than-expected corporate earnings and a potentially dovish Federal Reserve will continue to push U.S. stocks to fresh record highs.

Pfizer Receives Positive CHMP Opinion For TALZENNA® (talazoparib) For Patients With Inherited (Germline) BRCA-Mutated Locally Advanced Or Metastatic Breast Cancer

Pfizer Receives Positive CHMP Opinion For TALZENNA® (talazoparib) For Patients With Inherited (Germline) BRCA-Mutated Locally Advanced Or Metastatic Breast Cancer

Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA ® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP)...

Pfizer Becomes #4 Most Shorted Dow Stock, Replacing Merck

Pfizer Becomes #4 Most Shorted Dow Stock, Replacing Merck

The most recent short interest data has been released for the 04/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Pfizer Hosts Annual Meeting Of Shareholders

Pfizer Hosts Annual Meeting Of Shareholders

The board of directors of Pfizer Inc. today declared a 36-cent second-quarter 2019 dividend on the company's common stock, payable June 7, 2019 to shareholders of record at the close of business on May 10, 2019.

Pfizer And Lilly Announce Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis

Pfizer And Lilly Announce Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.

Be Careful With Healthcare Stocks Here

Be Careful With Healthcare Stocks Here

Especially when healthcare CEOs discus political issues with analysts and reporters.

Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of Shareholders

Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of Shareholders

Pfizer Inc. invites investors and the general public to listen to an audio webcast of the Annual Meeting of Shareholders at 9:00 a.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Pfizer Announces Presentation Of Data From A Phase 2 Study Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Announces Presentation Of Data From A Phase 2 Study Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Inc. (NYSE: PFE) announced today the presentation of data from a Phase 2 study of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia caused by...

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.

U.S. FDA Approves IBRANCE® (palbociclib) For The Treatment Of Men With HR , HER2- Metastatic Breast Cancer

U.S. FDA Approves IBRANCE® (palbociclib) For The Treatment Of Men With HR , HER2- Metastatic Breast Cancer

Pfizer (NYSE:PFE) today announced that the U.S.

TheStreet Quant Rating: B (Buy)